CN1748676A - Ligustilide oil and its preparation - Google Patents
Ligustilide oil and its preparation Download PDFInfo
- Publication number
- CN1748676A CN1748676A CN200510105552.XA CN200510105552A CN1748676A CN 1748676 A CN1748676 A CN 1748676A CN 200510105552 A CN200510105552 A CN 200510105552A CN 1748676 A CN1748676 A CN 1748676A
- Authority
- CN
- China
- Prior art keywords
- ligustilide
- oil
- petroleum ether
- preparation
- rhizoma chuanxiong
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 title claims abstract description 101
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 82
- 239000003208 petroleum Substances 0.000 claims abstract description 41
- 238000009835 boiling Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000003921 oil Substances 0.000 claims description 74
- 235000019198 oils Nutrition 0.000 claims description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 18
- 239000007901 soft capsule Substances 0.000 claims description 17
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 239000007902 hard capsule Substances 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 240000008415 Lactuca sativa Species 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 235000012045 salad Nutrition 0.000 claims description 6
- 235000019482 Palm oil Nutrition 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000002540 palm oil Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- 238000006424 Flood reaction Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 abstract description 3
- 229920001296 polysiloxane Polymers 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 8
- 229960001866 silicon dioxide Drugs 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960000715 nimodipine Drugs 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Abstract
The ligustilide oil with ligustilide content of 50-60 wt% is prepared through the following steps: 1. preparing coarse canidium oil; 2. adding petroleum ether of boiling range 30-60 deg c or 60-90 deg.c in the amount of 5 times the canidium oil to obtain petroleum ether solution; 3. treating the petroleum ether solution in silicone gel column; 4. eluting with petroleum ether; and 5. collecting the eluted liquid and concentrating to eliminating petroleum ether to obtain the ligustilide oil. The ligustilide oil may be further prepared into capsule preparation. The present invention has the advantages of high ligustilide content, low power consumption, reusability of solvent and silicone gel, low cost, etc, and is suitable for industrial production.
Description
The application is for dividing an application, and the application number of original application is 03153586.0, and the applying date is on August 18th, 2003.
Technical field
The present invention relates to a kind of ligustilide oil and preparation thereof, refer to especially a kind ofly from Rhizoma Chuanxiong, to extract, technology system, the ligustilide oil after the enrichment and the preparation thereof of enrichment ligustilide, belong to modern Chinese traditional medicine field.
Background technology
Ligustilide is one of main effective ingredient in the Rhizoma Chuanxiong, has anti-cerebral ischemia and improves cerebral blood flow, is used for the treatment of the various symptoms that caused by cerebral ischemia.
Because the pure product of ligustilide are unstable, all use at present with the form of Rhizoma Chuanxiong oil, the method of Rhizoma Chuanxiong oil available water steam distillation obtains, ligustilide content can reach more than 50% in the Rhizoma Chuanxiong oil that obtains from Rhizoma Chuanxiong, but because production process needs long Steam Heating (reaching several days) energy resource consumption very big, gained Rhizoma Chuanxiong oil collecting amount is very low, and the yield of ligustilide is lower.The also available CO of Rhizoma Chuanxiong oil
2Supercritical extraction method extracts, but ligustilide content in the gained Rhizoma Chuanxiong oil is used the HPLC internal mark method determination with ligustilide reference substance (purity reaches more than 98%), and its content has only 5～9%, and slightly oily with the Rhizoma Chuanxiong of 85% ethanol room temperature dipping gained, its ligustilide content only is 14%～18%.Therefore, study a kind of simplely, the process of enriching that can make ligustilide content reach the ligustilide oil more than 50% has Practical significance.
Summary of the invention
The purpose of this invention is to provide a kind of technology of enrichment ligustilide and the ligustilide oil that obtains.
Another object of the present invention provides the Rhizoma Ligustici pharmaceutical preparation of being rich in ligustilide.
For achieving the above object, the present invention is by the following technical solutions:
A kind of ligustilide oil, the content of ligustilide is 50～60% in the oil, is obtained by following prepared:
(1) the preparation Rhizoma Chuanxiong is slightly oily;
(2) overstriking oil 5 times of amounts, boiling ranges are the petroleum ether of 30～60 ℃ or 60 ℃～90 ℃, must petroleum ether solution;
(3) with 80～200 purpose silica gel of～2 times of amounts of thick oily 1.6 times of amounts, dress up short column, diameter and aspect ratio are 1: 1.3～1: the 1.5 above-mentioned petroleum ether solution of processing;
(4) after petroleum ether solution flows to end, wash post with the petroleum ether of 1～2 times of amount of thick oil in post;
(5) wash post with the petroleum ether of thick oily 12～16 times of amounts, collect eluent, be concentrated into petroleum ether to the greatest extent, promptly get ligustilide oil.
The described method of the thick oil of Rhizoma Chuanxiong for preparing of step (1) is for flooding Rhizoma Chuanxiong or CO with 85% ethanol room temperature
2Supercritical extraction obtains slightly oil of Rhizoma Chuanxiong.
Described 85% ethanol room temperature dipping is meant that the raw material that will contain ligustilide floods 3 times through four times of amount 85% ethanol room temperatures, obtains slightly oil of Rhizoma Chuanxiong.
Described CO
2Supercritical extraction is meant and will contains the raw material of ligustilide through CO
2Supercritical extraction, extraction conditions is: pressure 34.5MPa, 60 ℃ of temperature, modifier ethanol 0.3ml, 3 hours extraction time, the Rhizoma Chuanxiong oil that obtains.
This method is utilized following principle enrichment ligustilide: silica gel adsorption, the applied sample amount of overload.With common upper column quantity down can not the eluting ligustilide low polarity solvent, can separate eliminating than the more weak impurity of ligustilide absorption, the eluting ligustilide, but can not adsorb stronger impurity than ligustilide by eluting, thus reach the purpose of purification enrichment ligustilide.
With the ligustilide oil 25%～50% (its ligustilide content 50%～60%) of enrichment processing back gained, Petiolus Trachycarpi oil 3%～6%, hydrogenated palm oil 3%～6%, phosphatidase 12 %～4% and salad oil 42%～59%.Being mixed with soft capsule content, is rubber with glycerol-gelatin, is pressed into soft capsule, and every soft capsule contains ligustilide and is not less than 25mg and every soft capsule and contains ligustilide and be not less than 50mg.
With the ligustilide oil 20～80% (its ligustilide content 50%～60%) of enrichment processing back gained, fat-soluble excipient such as salad oil 80～20%, fill becomes liquid hard capsule, and every hard capsule contains ligustilide and is not less than 50mg.
The test of pesticide effectiveness shows that this product has anti-cerebral ischemia, is used for the treatment of the various symptoms that caused by cerebral ischemia.
Advantage of the present invention is: the ligustilide oil of back gained is handled in enrichment, and through being standard with the ligustilide reference substance, HPLC measures, and the content of ligustilide reaches 50～60% in the ligustilide oil.Energy low consumption, all technical process except that enrichment process, all is at room temperature to operate; Solvent for use and silica gel can be recycled, and cost is low; Ligustilide yield height; Technological operation is simple; Equipment needed thereby is simple, is suitable for industrialized great production.
Be described further below in conjunction with the preferable specific embodiment.
The specific embodiment
Embodiment 1, be the technology of raw material enrichment ligustilide with the Rhizoma Chuanxiong
One, material and method
1, material:
Rhizoma Chuanxiong: purchase in Tianjin medical material company
Ethanol: purchase in Tianjin Alcohol Plant
Silica gel: purchase in Haiyang Chemical Plant, Qingdao
Petroleum ether: purchase in Tianjin Milky Way chemical reagent work
The ligustilide reference substance: Rhizoma Chuanxiong by silicagel column, obtains grease through alcohol extraction, reaches ligustilide reference substance more than 98% obtaining content on the preparation HPLC, meets the requirement of reference substance.
2, method:
(1) Rhizoma Chuanxiong is flooded 3 times through four times of amount 85% ethanol room temperatures, obtain slightly oil of Rhizoma Chuanxiong;
(2) overstriking oil 5 times of amounts, boiling ranges are 60～90 ℃ petroleum ether, get petroleum ether solution;
(3) with 100～200 purpose silica gel of thick oily 1.8 times of amounts, dress up short column, diameter and aspect ratio are 1: 1.3 above-mentioned petroleum ether solution of processing;
(4) after petroleum ether solution flows to end, wash post with the petroleum ether of 1.5 times of amounts of thick oil in post;
(5) wash post with the petroleum ether of thick oily 12 times of amounts, collect eluent, be concentrated into petroleum ether to the greatest extent, promptly get ligustilide oil.
Two, detection and result:
Through being standard with the ligustilide reference substance, HPLC measures, C
18Post; Mobile phase is 64% methanol-1% glacial acetic acid; The detection wavelength is 272nm.The content of ligustilide reaches 15～17% in the thick oil of Rhizoma Chuanxiong, ligustilide yield 90～95%; The content of ligustilide reaches 50～60% in the ligustilide oil, ligustilide yield 85%.
Embodiment 2, be the technology of raw material enrichment ligustilide with the Rhizoma Chuanxiong
One, material and method
1, material: with embodiment 1.
2, method:
(1) Rhizoma Chuanxiong is flooded 3 times through four times of amount 85% ethanol room temperatures, obtain slightly oil of Rhizoma Chuanxiong;
(2) overstriking oil 5 times of amounts, boiling ranges are 30～60 ℃ petroleum ether, get petroleum ether solution;
(3) with 80～100 purpose silica gel of thick oily 2 times of amounts, dress up short column, diameter and aspect ratio are 1: 1.5 above-mentioned petroleum ether solution of processing;
(4) after petroleum ether solution flows to end, wash post with the petroleum ether of 2 times of amounts of thick oil in post;
(5) wash post with the petroleum ether of thick oily 16 times of amounts, collect eluent, be concentrated into petroleum ether to the greatest extent, promptly get ligustilide oil.
Two, detection and result:
Through being standard with the ligustilide reference substance, HPLC measures, and the content of ligustilide reaches 17% in the thick oil of Rhizoma Chuanxiong, ligustilide yield 90～95%; The content of ligustilide reaches 50～55% in the ligustilide oil, ligustilide yield 85%.
Embodiment 3, with CO
2The thick oil of the Rhizoma Chuanxiong of supercritical extraction method gained is the technology of raw material enrichment ligustilide
One, material and method
1, material: with embodiment 1.
2, method
(1) with Rhizoma Chuanxiong CO
2Supercritical extraction, CO
2The supercritical extraction condition is: pressure 34.5MPa, and 60 ℃ of temperature, modifier ethanol 0.3ml, 3 hours extraction time, the Rhizoma Chuanxiong that obtains is oil slightly;
(2) overstriking oil 5 times of amounts, boiling ranges are 60～90 ℃ of petroleum ether, get petroleum ether solution;
(3) with 100～200 purpose silica gel of thick oily 1.8 times of amounts, dress up short column, diameter and aspect ratio are 1: 1.4 above-mentioned petroleum ether solution of processing;
(4) after petroleum ether solution flows to end, wash post with the petroleum ether of 2 times of amounts of thick oil in post;
(5) wash post with the petroleum ether of thick oily 14 times of amounts, collect eluent, be concentrated into petroleum ether to the greatest extent, promptly get ligustilide oil.
Two, detection and result:
Through being standard with the ligustilide reference substance, HPLC measures, and the content of ligustilide reaches 8.8% in the thick oil of Rhizoma Chuanxiong; The content of ligustilide reaches 58% in the ligustilide oil, ligustilide yield 80%.
Embodiment 4, be rich in the preparation of ligustilide
One, prescription: ligustilide oil 50%, Petiolus Trachycarpi oil 3%, hydrogenated palm oil 3%, phosphatidase 12 % phospholipid and salad oil 42%.
Two, preparation method:
Being mixed with soft capsule content with formulation, is rubber with glycerol-gelatin, is pressed into soft capsule, and specification is every dress 0.2g content, and every soft capsule contains ligustilide and is not less than 50mg.
Consumption and usage: every day 2 times, each 1.(fixing tentatively)
Embodiment 5, be rich in the preparation of ligustilide
One, prescription: ligustilide oil 25%, Petiolus Trachycarpi oil 6%, hydrogenated palm oil 6%, phosphatidase 14 % phospholipid and salad oil 59%.
Two, preparation method:
Being mixed with soft capsule content with formulation, is rubber with glycerol-gelatin, is pressed into soft capsule, and specification is every dress 0.2g content, and every soft capsule contains ligustilide and is not less than 25mg.
Consumption and usage: every day 2 times, each 1.(fixing tentatively)
Embodiment 6, be rich in the preparation of ligustilide
One, prescription: ligustilide oil 25%, Petiolus Trachycarpi oil 6%, hydrogenated palm oil 6%, phosphatidase 14 % phospholipid and salad oil 59%.
Two, preparation method:
Being mixed with soft capsule content with formulation, is rubber with glycerol-gelatin, is pressed into soft capsule, and specification is every dress 0.4g content, and every soft capsule contains ligustilide and is not less than 50mg.
Embodiment 7, be rich in the preparation of ligustilide
One, prescription: ligustilide oil 40%, excipient 60%.
Two, preparation method:
With ligustilide oil and fat-soluble excipient mix homogeneously, fill is in hard capsule case, and employing joint filling material (HPMC
5cps5%, PVAl%, ethanol 34%, water 60%) the capsule shells suit place is carried out once or secondary seals, be prepared into liquid hard capsule, every hard capsule contains ligustilide and is not less than 50mg.
Embodiment 8, pharmacodynamic experiment
One, material and method:
1, animal: choose 51 of 22～27g kunming mices, male and female have concurrently, are divided into 5 groups at random, are respectively normal control group, nimodipine matched group, ligustilide line of oils.
2, method: nimodipine is selected intraperitoneal administration, each dosage group selection gastric infusion of ligustilide, and blank group gives the water with volume.Each is organized the mice administration and breaks end fast at the ear rear portion with shear after 1 hour, and clocks immediately.Continue the time of breathing of dehiscing behind the record mice broken end.
Two, result: can obviously prolong after nimodipine contrast, each dosage group mice administration of ligustilide and continue the time of breathing of dehiscing.
Claims (9)
1, a kind of ligustilide oil, the content of ligustilide is 50～60% in the oil, is obtained by following prepared:
(1) the preparation Rhizoma Chuanxiong is slightly oily;
(2) overstriking oil 5 times of amounts, boiling ranges are the petroleum ether of 30～60 ℃ or 60～90 ℃, must petroleum ether solution;
(3) with 80～200 purpose silica gel of～2 times of amounts of thick oily 1.6 times of amounts, dress up short column, diameter and aspect ratio are 1: 1.3～1: the 1.5 above-mentioned petroleum ether solution of processing;
(4) after petroleum ether solution flows to end, wash post with the petroleum ether of 1～2 times of amount of thick oil in post;
(5) wash post with the petroleum ether of thick oily 12～16 times of amounts, collect eluent, be concentrated into petroleum ether to the greatest extent, promptly get ligustilide oil.
2, a kind of ligustilide oil according to claim 1 is characterized in that: described step (1) prepares the method for the thick oil of Rhizoma Chuanxiong for Rhizoma Chuanxiong is flooded or CO with 85% ethanol room temperature
2Supercritical extraction obtains slightly oil of Rhizoma Chuanxiong.
3, a kind of ligustilide oil according to claim 2 is characterized in that: described 85% ethanol room temperature dipping is meant that the raw material that will contain ligustilide floods 3 times through four times of amount 85% ethanol room temperatures, obtains slightly oil of Rhizoma Chuanxiong.
4, a kind of ligustilide oil according to claim 2 is characterized in that: described CO
2Supercritical extraction is meant and will contains the raw material of ligustilide through CO
2Supercritical extraction, extraction conditions is: pressure 34.5MPa, 60 ℃ of temperature, modifier ethanol 0.3ml, 3 hours extraction time, the Rhizoma Chuanxiong oil that obtains.
5, a kind of preparation that is rich in ligustilide, it is characterized in that: said preparation is a soft capsule, with glycerol-gelatin is rubber, this soft capsule content contains the ligustilide oil 25～50% after the enrichment basically, Petiolus Trachycarpi oil 3%～6%, hydrogenated palm oil 3%～6%, phosphatidase 12 %～4% and salad oil 42%～59%.
6, a kind of preparation that is rich in ligustilide is characterized in that: said preparation is a liquid hard capsule, and this capsule 's content contains the ligustilide oil 20～80% after the enrichment basically, fat-soluble excipient 80～20%.
7, preparation according to claim 5 is characterized in that: every of described soft capsule contains ligustilide and is not less than 25mg.
8, preparation according to claim 5 is characterized in that: every of described soft capsule contains ligustilide and is not less than 50mg.
9, preparation according to claim 6 is characterized in that: every of described liquid hard capsule contains ligustilide and is not less than 50mg.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03153586 CN1247564C (en) | 2003-08-18 | 2003-08-18 | Enrichment of ligusticum lactone and its preparations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03153586 Division CN1247564C (en) | 2003-08-18 | 2003-08-18 | Enrichment of ligusticum lactone and its preparations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1748676A true CN1748676A (en) | 2006-03-22 |
| CN1321638C CN1321638C (en) | 2007-06-20 |
Family
ID=34597770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510105552XA Expired - Fee Related CN1321638C (en) | 2003-08-18 | 2003-08-18 | Ligustilide oil and its preparation |
| CN 03153586 Expired - Fee Related CN1247564C (en) | 2003-08-18 | 2003-08-18 | Enrichment of ligusticum lactone and its preparations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03153586 Expired - Fee Related CN1247564C (en) | 2003-08-18 | 2003-08-18 | Enrichment of ligusticum lactone and its preparations |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN1321638C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138135A (en) * | 2016-08-18 | 2016-11-23 | 四川省中医药科学院 | Medicine for treatment of vascular cognitive disorder and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321638C (en) * | 2003-08-18 | 2007-06-20 | 天津药物研究院 | Ligustilide oil and its preparation |
| CN102872175A (en) * | 2012-08-24 | 2013-01-16 | 天津中医药大学 | Ligusticum chuanxiong hort extract and preparation method and application thereof |
| CN105079059B (en) * | 2015-09-07 | 2020-03-31 | 宜诺(天津)医药工程有限公司 | Angelica sinensis extract and extraction method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1035327C (en) * | 1992-09-30 | 1997-07-02 | 兰州大学 | Synthetic method for rhizoma ligustici internal ester |
| CN1102397C (en) * | 2000-03-01 | 2003-03-05 | 山东绿叶制药股份有限公司 | Chinese angelica root oil soft capsule and its preparing process |
| US20030165580A1 (en) * | 2002-03-04 | 2003-09-04 | Xinxian Zhao | Safe pharmaceutical composition for treatment and prevention of gynecological disease |
| JP2003289827A (en) * | 2002-04-02 | 2003-10-14 | Osaka Yakuhin Kenkyusho:Kk | Supplement containing japanese parsley extract |
| CN100391953C (en) * | 2003-06-03 | 2008-06-04 | 北京九龙制药有限公司 | Medicinal use and extraction of cis-ligusticum lactone |
| US20040247698A1 (en) * | 2003-06-04 | 2004-12-09 | Valenzuela Cortes Carmen Maria | Erectile Dysfunction Treatment |
| CN1321638C (en) * | 2003-08-18 | 2007-06-20 | 天津药物研究院 | Ligustilide oil and its preparation |
-
2003
- 2003-08-18 CN CNB200510105552XA patent/CN1321638C/en not_active Expired - Fee Related
- 2003-08-18 CN CN 03153586 patent/CN1247564C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138135A (en) * | 2016-08-18 | 2016-11-23 | 四川省中医药科学院 | Medicine for treatment of vascular cognitive disorder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1321638C (en) | 2007-06-20 |
| CN1583735A (en) | 2005-02-23 |
| CN1247564C (en) | 2006-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105131142B (en) | Industrialization production method and application of acanthopanax senticosus polysaccharide | |
| CN1974527A (en) | Process of preparing high purity chlorogenic acid and flavonid with eucommia leaf | |
| CN1857589A (en) | Method of measuring icariin and epimedin c content in Xianlinggubao preparation | |
| CN1857421A (en) | Preparing method of total corydaline extract and corydalis preparation | |
| CN1112366C (en) | Extraction of gensenoside | |
| CN1943619A (en) | Method for preparing Chinese medicine origanum volatile oil and its soft capsule | |
| CN1748676A (en) | Ligustilide oil and its preparation | |
| CN1915319A (en) | Composition of Chinese traditional medicine in use for treating female inflammation | |
| CN1084187C (en) | Method for preparing anti-cancer medicine using beta-elemene as main effective ingredient, and components of the medicine | |
| CN1965898A (en) | Compound capsule of red sage root and method for preparing same | |
| CN1279052C (en) | Process for extracting total flavone and total oside of astragalus from astragalus | |
| CN1151821C (en) | Grape seed preparation and its extracting process | |
| CN1226303C (en) | High yield environmental protection type industrial separating method for ginseng saponin Rb1 | |
| CN1566137A (en) | Production process for platycodin | |
| CN1775263A (en) | Qiju-dihuang preparation and new preparation method | |
| CN1233401C (en) | Agastache capsule for restoring healthy energy andits prepn and application | |
| CN106916859B (en) | Method for rapidly extracting liquiritigenin from liquorice waste residue | |
| CN101780114A (en) | Extraction and separation method of effective constituents of traditional Chinese medicine | |
| CN1660364A (en) | 'Lianzhi' anti inflammation drop pill in use for clearing away heat and toxic material and preparation method | |
| CN1686434A (en) | Compound mactra clam drip pill and its preparation method | |
| CN1751706A (en) | Method for extraction of red-rooted salvia | |
| CN1360931A (en) | Nanometer luminous Dendrobium nobil medicine and its prepn | |
| CN1541669A (en) | Prepared traditional Chinese drug Liangfu drop pills for treating epigastric pain | |
| CN1301096C (en) | Cordyceps drip pill used for nourishing lung and kidney and its preparation method | |
| CN1957982A (en) | Extractive of red sage root, preparation and producing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN TAIPU MEDICAL INTELLECTUAL PROPERTY CIRCUL Free format text: FORMER OWNER: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Effective date: 20120110 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120110 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: TIANJIN TIPR PHARMACEUTICAL INTELLECTUAL PROPERTY TRANSFER CENTER Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research |
|
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH Free format text: FORMER OWNER: TIANJIN TAIPU PHARMACEUTICAL INTELLECTUAL PROPERTY TRANSFER RESERVE CENTER CO., LTD. Effective date: 20140520 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140520 Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee after: Tianjin Institute of Pharmaceutical Research Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: TIANJIN TIPR PHARMACEUTICAL INTELLECTUAL PROPERTY TRANSFER CENTER |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wu Jiang Document name: Notice of termination of patent right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070620 Termination date: 20210818 |